CLVS - Clovis Oncology, Inc.
12.80 0.00 (0.00%)
After hours: 5:04PM EDT
| Previous Close | 12.96 |
| Open | 12.98 |
| Bid | 12.82 x 1800 |
| Ask | 12.90 x 4000 |
| Day's Range | 12.72 - 13.36 |
| 52 Week Range | 11.50 - 48.32 |
| Volume | 1,351,023 |
| Avg. Volume | 1,655,143 |
| Market Cap | 697.432M |
| Beta (3Y Monthly) | 1.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.16 |
| Earnings Date | Jul 30, 2019 - Aug 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.50 |
- Zacks•7 hours ago
Glaxo's Zejula Meets Goal in First-Line Ovarian Cancer Study
Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer meets the primary endpoint.
- Simply Wall St.•4 days ago
Does Clovis Oncology, Inc. (NASDAQ:CLVS) Have A Particularly Volatile Share Price?
Anyone researching Clovis Oncology, Inc. (NASDAQ:CLVS) might want to consider the historical volatility of the share...
- Zacks•14 days ago
Do Options Traders Know Something About Clovis (CLVS) Stock We Don't?
Investors need to pay close attention to Clovis (CLVS) stock based on the movements in the options market lately.
- Zacks•22 days ago
Pfizer's Talzenna Gets Approval in Europe for Breast Cancer
Pfizer's (PFE) PARP inhibitor, Talzenna, receives approval in Europe for treating BRCA-mutated locally advanced or metastatic breast cancer.
- Zacks•28 days ago
AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
- Markit•28 days ago
See what the IHS Markit Score report has to say about Clovis Oncology Inc.
Clovis Oncology Inc NASDAQ/NGS:CLVSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 14. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CLVS are favorable, with net inflows of $2.40 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Insider Monkey•last month
Is Clovis Oncology Inc (CLVS) A Good Stock To Buy?
Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]
- Benzinga•last month
The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 6) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: ...
- Business Wire•last month
Clovis Oncology Names Ginger L. Graham as New Board of Directors Chair
“I am very pleased to announce that Ginger Graham is assuming the role of our Board Chair at Clovis Oncology. As an active Clovis board member for six years, Ginger is extremely familiar with our organization and will bring her tremendous expertise as a healthcare executive to her elevated role as Board Chair,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology.
- Zacks•last month
Why Is Clovis (CLVS) Down 25.3% Since Last Earnings Report?
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire•last month
Expanded Rubraca® (Rucaparib) Data from Clovis Oncology’s ARIEL3 and TRITON2 Trials in Ovarian and Prostate Cancers to be Presented at 2019 ASCO Annual Meeting
BOULDER, Colo.-- -- In exploratory analysis of ARIEL3 data, Rubraca significantly improved clinically meaningful endpoints including chemotherapy free interval and PFS on next therapy line for women with advanced ovarian cancer in maintenance treatment setting Updated Rubraca safety profile was consistent with the safety profile previously observed in ARIEL3 TRITON2 findings show that tumor tissue ...
- Investor's Business Daily•2 months ago
Biotech Stocks Clobbered As Two Slammed With Sell Ratings
Clovis Oncology and Esperion Therapeutics stocks skidded Wednesday after an analyst downgraded the biotech companies to sell ratings amid rising competition in their respective markets.
- Barrons.com•2 months ago
Clovis Oncology Stock Sinks on Dim View of Cancer Drug Sales
Shares of the biotech firm sank Wednesday morning after an analyst at Goldman Sachs downgraded the stock from Neutral to Sell.
- Business Wire•2 months ago
Clovis Oncology Presents Patient-Centered Outcomes Data from Phase 3 ARIEL3 Study for Rubraca®▼ in Advanced Ovarian Cancer
Quality-adjusted progression free survival and quality-adjusted time without cancer related symptoms or toxicity demonstrate the benefit of Rubraca maintenance t
- Business Wire•2 months ago
Clovis Oncology Announces Presentations at 2019 ASCO Annual Meeting
Accepted abstracts highlight additional data from phase 3 ARIEL3 clinical trial, genomic data from phase 2 TRITON2 clinical trial, and the designs of other ongoing rucaparib trials
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CLVS earnings conference call or presentation 7-May-19 12:30pm GMT
Q1 2019 Clovis Oncology Inc Earnings Call
- Zacks•2 months ago
Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong
Clovis (CLVS) reports encouraging first-quarter 2019 results. Rubraca maintains market share during the quarter.
Motley Fool•2 months agoClovis Oncology (CLVS) Q1 2019 Earnings Call Transcript
CLVS earnings call for the period ending March 31, 2019.
- Zacks•2 months ago
Clovis Oncology (CLVS) Reports Q1 Loss, Tops Revenue Estimates
Clovis (CLVS) delivered earnings and revenue surprises of 9.44% and 4.53%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Clovis: 1Q Earnings Snapshot
The Boulder, Colorado-based company said it had a loss of $1.63 per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...
- Business Wire•2 months ago
Clovis Oncology Announces First Quarter 2019 Operating Results
BOULDER, Colo.-- -- $33.1M in Rubraca ® global sales for the first quarter of 2018 Updated data on 52 patients with BRCA-mutant mCRPC provided to FDA; RECIST response rate highly consistent with that shown at ESMO 2018 Targeting late 2019 for supplemental NDA filing for BRCA-mutant advanced prostate cancer; data update expected at Fall 2019 medical meeting Clovis-sponsored combination studies of lucitanib ...
